carlisle medical
Refill Requests shipment tracking contact carlisle medical
knowledge center
industry news
Gabapentin Now a Controlled Substance in Michigan
The Licensing and Regulatory Affairs Department in Michigan recently released changes to the state Controlled Substance Rules. These rules include the addition of gabapentin to the Schedule V list as a controlled substance. Michigan follows... Full Story
FDA Announces Manufacturer Recall of Valsartan Products
The medications, Valsartan and Valsartan-Hydrochlorothiazide, are being recalled by Prinston Pharmaceutical Inc. These medications may be manufactured by Major Pharmaceuticals, Solco Healthcare, and Teva Pharmaceuticals. Currently, the recall is... Full Story
New Opioid Regulations for Tennessee
Starting July 1, 2018, several new regulations went into effect for the State of Tennessee. The “TN Together” legislation is aimed at the state’s opioid epidemic and is a comprehensive plan to address opioid abuse. Although the legislation took... Full Story
Florida Controlled Substances Bill Takes Effect July 1, 2018
Florida has joined other states in enacting legislation designed to battle the nation’s Opioid Crisis. The majority of provisions in Florida’s Controlled Substances Bill, CS/CS/HB 21, will go into effect July 1, 2018. The law addresses opioid abuse... Full Story
Arkansas Workers’ Compensation Commission Adopts New Rule
As you are aware, the Arkansas Workers' Compensation Commission has announced the adoption of Rule 099.41. The Rule has been approved by the Arkansas Legislative Council and will take effect on July 1, 2018. This Rule incorporates the following... Full Story
South Carolina Establishes Limits for Initial Opioid Prescriptions
South Carolina has been added to a growing number of states that have enacted legislation to limit initial opioid prescriptions in certain circumstances. The Amendment states that “initial opioid prescriptions for acute pain management or... Full Story
New Jersey Requires State Reporting for Gabapentin
New Jersey has joined several other states requiring the reporting of Gabapentin to state Prescription Monitoring Programs (PMPs). Gabapentin is a widely-prescribed medication often used to treat seizures and neuropathic pain. Many states have... Full Story
North Carolina Adopts Opioid Utilization Rules
The North Carolina Industrial Commission has adopted new rules for the utilization of opioids, related prescriptions and pain management treatment in workers' compensation claims. The new rules go into effect May 1, 2018. Included in the rules... Full Story
DEA To Share Painkiller Prescription Information With 48 States
WASHINGTON—Attorney General Jeff Sessions announced today that the Drug Enforcement Administration (DEA) has reached a prescription drug information-sharing agreement with 48 Attorneys General. “Better information means better decisions,”... Full Story
State of California Adopts New Drug Formulary
The State of California’s Division of Workers’ Compensation (DWC) has announced its final approval to adopt a new drug formulary for the medical treatment of injured workers. The formulary will go into effect for new injuries January 1, 2018.... Full Story
FDA Advisory for Limbrel Capsules
The U.S. Food and Drug Administration (FDA) has issued an advisory for the Primus Pharmaceuticals product, Limbrel, due to potential serious adverse events. Limbrel is a medical food composed of two types of flavonoids, biacalin and catechin. Both... Full Story
FDA Approves Lyrica CR
The FDA recently approved an extended-release version of Pfizer’s Lyrica, Lyrica CR. Lyrica CR is approved for once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy and the management of... Full Story
Ohio Enacts Limits on Opioid Prescriptions
Starting August 31, 2017, Ohio joins other states that have enacted limits when prescribing opioids for acute pain. Ohio’s new law will allow a seven-day supply of opioids for adults and five days for minors after parental consent. The total... Full Story
Kentucky Law Restricts Opioid Prescribing
Kentucky is following several other states that have recently enacted new laws to restrict opioid prescribing. House Bill 333 will restrict opioid prescriptions for acute pain to three days. Kentucky used 2016 CDC Guidelines for Prescribing Opioids... Full Story
DEA Proposes Reduction in Manufacturing of Opioids for 2018
The DEA has proposed to reduce the manufacturing of controlled substances in the United States for 2018 by 20% when compared to 2017. The change is due to a decrease in the demand of opioids such as oxycodone, hydrocodone, oxymorphone,... Full Story
Louisiana Enacts New Laws Regarding Opioid Prescribing Limits
Louisiana joined several states in enacting new laws limiting the days’ supply of a new opioid medication that can be dispensed. Act 82 states that for adults in outpatient settings with acute conditions, no more than a seven-day supply on a... Full Story
Endo Pharmaceuticals, Inc. Announces Withdrawal of Opana ER
Endo Pharmaceuticals announced it would be voluntarily withdrawing Opana ER (Oxymorphone ER) from the market. In June, the FDA requested that Endo remove Opana due to public health concerns regarding abuse of the medication. The FDA stated “after... Full Story
Gabapentin to Become a Controlled Substance in Kentucky
Kentucky will become the first state to change gabapentin to a Schedule V controlled substance, effective July 1, 2017. Current FDA-approved indications for gabapentin are post-herpetic neuralgia and seizures. However, gabapentin is most often... Full Story
New Jersey Governor Signs Opioid Restriction Law
New Jersey Governor, Chris Christie, signed new legislation recently to help curb the opioid epidemic in his state. The new legislation, Bill 3, limits initial opioid prescriptions for acute pain to a five-day supply and requires the prescriber to... Full Story
FDA Approves Vantrela ER
Vantrela ER (Hydrocodone Bitartrate) from Teva Pharmaceuticals has recently been granted approval from the FDA. Vantrela ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for... Full Story
Pennsylvania Passes Legislation Aimed at Reducing Opioid Abuse
Pennsylvania joins several states, including New York and Rhode Island, that have passed new opioid regulations aimed at reducing opioid abuse and deaths from overdoses. In November Pennsylvania Governor, Tom Wolf, signed several bills that either... Full Story
DEA Reduces Amount of Opioid Controlled Substances in 2017
The U.S. Drug Enforcement Administration (DEA) has published a Final Order on its website stating it will be reducing the amount of opioid medications that may be manufactured in the United States in 2017 by 25%. The manufacturing of certain opioid... Full Story
FDA Approves Troxyca ER
Troxyca ER (Oxycodone/Naltrexone) is a new Schedule II opioid from Pfizer Pharmaceuticals that recently received approval from the FDA (U.S. Food and Drug Administration). Troxyca ER is indicated for the management of pain severe enough to require... Full Story
NY: Initial Opioid Prescribing Limit Reduced to Seven Days for Acute Pain
The State of New York recently enacted several new measures to address the heroin and opioid abuse crisis in New York. One part of this legislation is aimed at reducing the overprescribing of opioids in acute pain situations.... Full Story
New Schedule II Opioids Introduced
Oxaydo™, a Schedule II opioid, is the first and only immediate-release formulation of Oxycodone HCL that discourages intranasal abuse and is indicated for the management of acute and chronic moderate to severe pain, where the use of an opioid... Full Story
Tennessee Publishes Rules on Treatment Guidelines and Drug Formulary
Tennessee Publishes Rules on Treatment Guidelines and Drug Formulary The Tennessee Attorney General has approved new treatment guidelines and a closed drug formulary proposed by the Tennessee Bureau of Workers’ Compensation. The rule will next go... Full Story
2016 Georgia Update – Case Management Changes
Effective January 1, 2016 the Georgia State Board of Workers’ Compensation has implemented a change to Rule 200.2. To view and download the minutes from the Georgia State Board of Workers’ Compensation, click the link... Full Story
Launch of Hysingla ER
The Federal Drug Administration (FDA) has approved the release of Hysingla ER, the first hard-to-abuse version of hydrocodone. Hysingla ER is an extended release opioid used to treat severe pain and should not be used for as-needed pain relief. The... Full Story
New Rule for Hydrocodone
The U. S. Drug Enforcement Agency (DEA) has published its final rule for hydrocodone combination products, changing its drug classification from a Schedule III to a Schedule II medication, as defined in the Controlled Substances Act. Hydrocodone is... Full Story
FDA Approves New Extended-Release Oxycodone with Abuse-Deterrent Properties
"Today, the U.S. Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), an extended-release/long-acting (ER/LA) opioid analgesic to treat pain severe enough to require daily,... Full Story
Louisiana: Carisoprodol (Soma) Placed in Schedule II Classification
Act 397 (SB 618) of 2014 Legislature - effective August 1. 2014. This law places carisoprodol (Soma) products with the exception of the combination product with codeine) in Schedule II of the Louisiana Uniform Controlled Substances Law. These... Full Story
DEA Finalizes Rule to Schedule Tramadol
On July 2, 2014, the Drug Enforcement Administration (DEA) published in the Federal Register the final rule placing tramadol into Schedule IV of the Controlled Substances Act. This rule will become effective on August 18, 2014. At this time, all... Full Story
FDA Recommends Decreased Dosage Of Lunesta
The U.S. Food and Drug Administration (FDA) has released a Safety Announcement which states: “The U.S. Food and Drug Administration (FDA) is warning that the insomnia drug Lunesta (eszopiclone) can cause next-day impairment of driving and other... Full Story
In its January 10, 2014 notice in the Federal Register, the FDA ordered drug companies to stop the manufacturing of unapproved products from the following prescription drug list: > Single-ingredient codeine sulfate oral tablets; > ... Full Story
FDA Approval for ZORVOLEX™
October 18, 2013 – Iroko Pharmaceuticals, LLC, announced that the FDA had approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX™ was approved at... Full Story
FDA bans generic version of Oxycontin
On the day when the patent for the original version of OxyContin was set to expire the Food and Drug Administration said Tuesday that it would not approve generic versions of the powerful narcotic Oxycontin. The move represents a victory for... Full Story
Changes to the Controlled Substance Schedules - New York
Changes to the Controlled Substance Schedules in Section 3306 of the New York State Public Health Law per the Bureau of Narcotic Enforcement (, effective February 23, 2013, the following changes will... Full Story
Illinois - Final Physician-Dispensed Pharmacy Rule Published
The IWCC's final repackaged drug repricing methodology was published in the December 7 edition of the Illinois Register. As we covered in our 11/20/2012 post, the effective date of the change is November 20, 2012. The Medical Fee Advisory Board... Full Story
Notes from the Pharmacists: Suboxone® Tablets
Suboxone® (buprenorphine /naloxone) tablets were developed to prevent abuse. The naloxone in the Suboxone® tablet is there to discourage people from dissolving the tablet and injecting it. When a Suboxone® Tablet is placed under the tongue, as... Full Story
Company News
Generic Releases
Industry Related News
Industry Related Links
Newsletter Subscription
Newsletter Login
© Copyright 2019 Carlisle Medical, Inc.
Twitter Twitter Twitter Twitter
disclaimer site map disclaimer